http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101542891-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2013-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101542891-B1 |
| titleOfInvention | A new BIM BH3 mutant peptide activated by Akt for killing cancer cells selectively |
| abstract | The present invention relates to a novel BIM (Bcl-2-interacting mediator of cell death) BH3 mutant polypeptide which is activated by Akt and selectively kills cancer cells, a gene encoding the same, and a polypeptide comprising the polypeptide and a cell membrane- ≪ / RTI > The present invention also provides a composition for suppressing cancer comprising the polypeptide, the gene or the fusion protein. The composition for inhibiting cancer of the present invention is useful for treating cancer that is activated with Akt, namely, brain tumor, ovarian cancer, breast cancer, endometrial cancer, liver cancer, melanoma, digestive cancer, lung cancer, kidney cancer, thyroid cancer, lymphoma cancer and prostate cancer Can be usefully used. |
| priorityDate | 2013-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.